Cargando…

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma

Argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for arginine biosynthesis, is expressed in many types of human malignancies. Recent studies showed that ASS1 may have tumor suppressor function and that ASS1 deficiency is associated with clinical aggressiveness in nasopharyngeal carcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Qingqing, Stewart, John, Wang, Hua, Rashid, Asif, Zhao, Jun, Katz, Matthew H., Lee, Jeffrey E., Fleming, Jason B., Maitra, Anirban, Wolff, Robert A., Varadhachary, Gauri R., Krishnan, Sunil, Wang, Huamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302782/ https://www.ncbi.nlm.nih.gov/pubmed/28187218 http://dx.doi.org/10.1371/journal.pone.0171985

Ejemplares similares

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
por: Syed, N, et al.
Publicado: (2013)

Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis
por: van der Meer, Jonathan H. M., et al.
Publicado: (2021)

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study
por: Zaid, Mohamed, et al.
Publicado: (2020)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

A transgenic approach to study argininosuccinate synthetase gene expression
por: Shiue, Shih-Chang, et al.
Publicado: (2014)

Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
por: Amer, Ahmed M., et al.
Publicado: (2018)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

Cytosolic Delivery of Argininosuccinate Synthetase Using a Cell-Permeant Miniature Protein
por: Knox, Susan L., et al.
Publicado: (2021)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer
por: SHAN, YAN-SHEN, et al.
Publicado: (2015)

Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance
por: Kim, Youngji, et al.
Publicado: (2016)

Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model
por: Shiue, Shih-Chang, et al.
Publicado: (2015)

Citrullinemia type I in Chinese children: Identification of two novel argininosuccinate synthetase gene mutations
por: Xiong, Mei, et al.
Publicado: (2022)

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
por: Shan, Yan-Shen, et al.
Publicado: (2015)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

High-throughput enrichment of temperature-sensitive argininosuccinate synthetase for two-stage citrulline production in E. coli
por: Schramm, Thorben, et al.
Publicado: (2020)

Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy
por: Liang, Tom Z., et al.
Publicado: (2023)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
por: Ottenhof, Niki A., et al.
Publicado: (2011)

Genetics and biology of pancreatic ductal adenocarcinoma
por: Ying, Haoqiang, et al.
Publicado: (2016)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
por: Wu, Fe-Lin Lin, et al.
Publicado: (2011)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
por: Delage, B, et al.
Publicado: (2012)

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
por: Kim, Stephanie S., et al.
Publicado: (2020)

Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines
por: Roeksomtawin, Somphon, et al.
Publicado: (2018)

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma
por: Overman, Michael J., et al.
Publicado: (2016)

Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
por: Taherian, Mehran, et al.
Publicado: (2022)

3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma
por: Kang, Ya’an, et al.
Publicado: (2022)

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
por: Liu, Jiangbo, et al.
Publicado: (2014)

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
por: Koay, Eugene J., et al.
Publicado: (2019)

Oligoadenylate synthetases-like is a prognostic biomarker and therapeutic target in pancreatic ductal adenocarcinoma
por: Chen, Shihong, et al.
Publicado: (2022)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy
por: McAlpine, Jennifer A, et al.
Publicado: (2014)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer
por: Douglas, Julia E., et al.
Publicado: (2022)

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
por: Szlosarek, Peter W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2o73ucvp1rrus8irorakk9gol2